An interventional study of Simulation-Free Single-Fraction Radiation Therapy (4 Gy × 1) in Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma and Follicular Lymphoma, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada — 5 open to participants now, 13 under way, 2 of them phase 3. Lymphoma, B-Cell, Marginal Zone · Canada.
Among the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada, this one is the 20th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2026, is the only one with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 33rd registered.
877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.
Browse Lymphoma, B-Cell, Marginal Zone studies →5 of the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Canada, United States, Australia and 9 more countries
Ages 18+
British Columbia Cancer Agency · Sites in Canada
Ages 19–100
International Extranodal Lymphoma Study Group (IELSG) · Sites in Canada, United States, Argentina and 12 more countries
Ages 18+
BeOne Medicines · Sites in Canada, United States, Australia and 13 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 9 · Phase 3 9
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 683 interventional studies indexed under Lymphoma, B-Cell, Marginal Zone.
Median enrollment 87 across the 30 interventional studies, 174 across the 3 observational. Of the 20 that completed or were terminated, 4 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,440 studies on the registry; 297 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 1 study filed under Lymphoma, B-Cell, Marginal Zone — fewer than ten, so there is no comparison to draw.
4 of the studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700149International Extranodal Lymphoma Study Group (IELSG)Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | 2026-12-31 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT06224309British Columbia Cancer AgencyPreliminary Assessment of [18F]BL40 in PET/CT Scans | 2027-03-15 |
| NCT07101328Eli Lilly and CompanyA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study will evaluate whether people with indolent B-cell lymphoma can receive radiation therapy without a separate computed tomography (CT) simulation appointment. Participants will receive one low-dose radiation treatment of 4 gray (Gy). Treatment planning will use a recent diagnostic CT scan, and cone-beam computed tomography (CBCT) imaging on the treatment day will be used to confirm participant positioning and adjust the treatment plan if needed.
The study includes participants with orbital or ocular adnexal lymphoma and participants with lymphoma at other body sites. The investigators will assess whether simulation-free treatment can be completed successfully, treatment duration, the number of hospital visits required, treatment side effects, patient-reported symptoms, control of the treated lymphoma site, and the need for additional treatment. Participants will be followed for up to 12 months.
This prospective, single-centre, single-arm pilot feasibility study evaluates a simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy workflow for participants with indolent B-cell lymphoma.
Participants will receive single-fraction ultra-low-dose radiation therapy consisting of 4 Gy delivered in one treatment session. Instead of undergoing a separate CT simulation, treatment planning will use a recent diagnostic CT scan suitable for contouring and dose calculation.
On the treatment day, CBCT imaging will be obtained to confirm participant positioning and anatomy. The treatment plan may be adapted while the participant is on the treatment couch and will be reviewed and approved before radiation delivery.
The study includes two cohorts:
Participants with orbital or ocular adnexal indolent B-cell lymphoma.
Participants with non-orbital indolent B-cell lymphoma.
If an acceptable simulation-free treatment plan cannot be produced, the participant will proceed through the standard CT simulation-based treatment process. This will be recorded as an unsuccessful simulation-free workflow but will not prevent the participant from receiving clinically appropriate treatment.
The primary objective is to determine the proportion of participants who successfully complete treatment without requiring conventional CT simulation.
Secondary assessments include treatment timing, on-couch time, hospital visits avoided, reasons for workflow failure, treatment-related side effects, patient-reported symptoms, local control of the treated site at 6 months, and retreatment of the treated site within 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy delivered as a single 4 gray (Gy) fraction. Treatment planning will use a recent diagnostic computed tomography (CT) scan instead of a separate planning CT simulation. CBCT imaging will be obtained on the treatment day to confirm positioning and anatomy and to adapt the treatment plan when needed. Participants for whom the simulation-free workflow is not feasible will proceed to standard CT simulation-based treatment.
Radiation: Simulation-Free Single-Fraction Radiation Therapy (4 Gy × 1)
Participants will receive a single 4 gray (Gy) fraction of radiation therapy using a simulation-free workflow. A recent diagnostic computed tomography (CT) scan suitable for contouring and dose calculation will be used for initial treatment planning instead of a separate planning CT simulation. On the treatment day, cone-beam computed tomography (CBCT) imaging will be obtained to confirm positioning and anatomy. The treatment plan may be adapted on the treatment couch and will undergo physician and physics review before radiation is delivered. If a clinically acceptable simulation-free plan cannot be produced, the participant will proceed to the standard CT simulation-based workflow.
Also known as: Ultra-Low-Dose Radiation Therapy, CBCT-Guided Adaptive Radiation Therapy, Diagnostic CT-Based Radiation Treatment Planning
Successful Completion of Simulation-Free Radiation Therapy
Proportion of participants who successfully complete the prescribed single-fraction 4 Gy radiation treatment using the simulation-free, cone-beam CT-guided adaptive workflow without requiring fallback to conventional CT simulation. The workflow will be considered feasible if at least 80% of participants complete treatment without conventional CT simulation.
Time frame: Periprocedural (single radiation treatment session)
Time From Radiation Oncology Consultation to Treatment
Number of calendar days between the radiation oncology consultation date and the date of radiation treatment.
Time frame: From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks
Same-Day Treatment
Proportion of participants who receive radiation treatment on the same calendar day as their radiation oncology consultation.
Time frame: Day 1 (date of radiation oncology consultation)
Total On-Couch Time
Total number of minutes the participant spends on the treatment couch, measured from initial positioning to completion of radiation delivery.
Time frame: Periprocedural (single radiation treatment session)
Number of Hospital Visits
Number of hospital visits occurring between referral to Radiation Oncology and completion of radiation treatment. The observed number will be used to estimate visits avoided compared with the conventional CT simulation-based workflow.
Time frame: From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks
CT Simulation Avoided
Proportion of participants who complete radiation treatment without requiring a separate conventional CT simulation appointment.
Time frame: Periprocedural (through completion of the single radiation treatment session)
Reasons for Simulation-Free Workflow Failure
Reasons that the simulation-free workflow could not be completed, including inadequate diagnostic imaging, changes in anatomy, positioning difficulties, inadequate cone-beam CT visualization, or inability to produce an acceptable treatment plan.
Time frame: From treatment planning through radiation treatment completion, up to 4 weeks
Clinician-Graded Treatment-Related Toxicity
Incidence and severity of treatment-related adverse events assessed using the Common Terminology Criteria for Adverse Events, version 5.0. The proportions of participants experiencing Grade 2 or higher and Grade 3 or higher events will be reported.
Time frame: Baseline, 2-4 weeks, and 3 months after treatment
Ocular Surface Disease Index Score
Change in Ocular Surface Disease Index score among participants with orbital or ocular adnexal lymphoma. Higher scores indicate greater ocular-surface-related symptoms and functional impairment.
Time frame: Baseline, 2-4 weeks, and 3 months after treatment
Head and Neck Quality-of-Life Symptoms
Change in relevant patient-reported symptoms measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 43 among applicable participants with head-and-neck treatment sites.
Time frame: Baseline, 2-4 weeks, and 3 months after treatment
Index Symptom Severity
Change in the participant's main treatment-related symptom measured using a numeric rating scale from 0 to 10, where 0 indicates no symptom and 10 indicates the worst imaginable symptom.
Time frame: Baseline, 2-4 weeks, and 3 months after treatment
Local Control of the Treated Site
Proportion of participants without radiographic or clinical progression within the irradiated site. Local control will be determined using the best routinely available assessment modality, which may include PET/CT, CT, MRI, ophthalmologic assessment, or clinical examination.
Time frame: 6 months after radiation treatment
Retreatment of the Treated Site
Proportion of participants who require additional local or systemic treatment for inadequate response or progression at the irradiated site.
Time frame: Within 12 months after radiation treatment
Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, B-Cell, Marginal Zone →
University Health Network, Toronto →